Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Non-Current Debt (2019 - 2025)

China SXT Pharmaceuticals has reported Non-Current Debt over the past 6 years, most recently at $73102.0 for Q3 2025.

  • For Q3 2025, Non-Current Debt fell 36.62% year-over-year to $73102.0; the TTM value through Sep 2025 reached $73102.0, down 36.62%, while the annual FY2025 figure was $96264.0, 17.81% down from the prior year.
  • Non-Current Debt for Q3 2025 was $73102.0 at China SXT Pharmaceuticals, down from $96264.0 in the prior quarter.
  • Over five years, Non-Current Debt peaked at $117862.0 in Q1 2023 and troughed at $6292.0 in Q1 2021.
  • A 4-year average of $90366.9 and a median of $106575.0 in 2023 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: plummeted 82.77% in 2021 and later increased 8.23% in 2024.
  • Year by year, Non-Current Debt stood at $6292.0 in 2021, then skyrocketed by 1593.82% to $106575.0 in 2023, then grew by 8.23% to $115344.0 in 2024, then crashed by 36.62% to $73102.0 in 2025.
  • Business Quant data shows Non-Current Debt for SXTC at $73102.0 in Q3 2025, $96264.0 in Q1 2025, and $115344.0 in Q3 2024.